Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Standard BioTools Inc. stock logo
LAB
Standard BioTools
$0.57
+5.7%
$0.67
$0.39
▼
$1.72
$212.95M1.521.03 million shs697,470 shs
MaxCyte, Inc. stock logo
MXCT
MaxCyte
$1.25
+6.8%
$1.25
$0.64
▼
$1.81
$120.80M1.491.47 million shs975,795 shs
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
$2.43
+3.0%
$1.95
$0.84
▼
$4.31
$300.60M0.667.63 million shs4.55 million shs
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
$18.50
$18.48
$11.09
▼
$21.01
$374.16M1.31253,980 shsN/A
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Standard BioTools Inc. stock logo
LAB
Standard BioTools
+5.67%-11.35%-11.39%-11.81%-54.03%
MaxCyte, Inc. stock logo
MXCT
MaxCyte
+6.84%+13.64%-3.85%-9.42%-26.90%
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
+2.97%+0.41%-7.60%+169.31%+9.95%
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
0.00%0.00%0.00%+0.65%+13.29%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Standard BioTools Inc. stock logo
LAB
Standard BioTools
$0.57
+5.7%
$0.67
$0.39
▼
$1.72
$212.95M1.521.03 million shs697,470 shs
MaxCyte, Inc. stock logo
MXCT
MaxCyte
$1.25
+6.8%
$1.25
$0.64
▼
$1.81
$120.80M1.491.47 million shs975,795 shs
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
$2.43
+3.0%
$1.95
$0.84
▼
$4.31
$300.60M0.667.63 million shs4.55 million shs
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
$18.50
$18.48
$11.09
▼
$21.01
$374.16M1.31253,980 shsN/A
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Standard BioTools Inc. stock logo
LAB
Standard BioTools
+5.67%-11.35%-11.39%-11.81%-54.03%
MaxCyte, Inc. stock logo
MXCT
MaxCyte
+6.84%+13.64%-3.85%-9.42%-26.90%
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
+2.97%+0.41%-7.60%+169.31%+9.95%
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
0.00%0.00%0.00%+0.65%+13.29%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Standard BioTools Inc. stock logo
LAB
Standard BioTools
1.50
ReduceN/AN/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
2.00
Hold$4.50260.00% Upside
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
2.60
Moderate Buy$3.8357.75% Upside
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
1.83
Reduce$17.25-6.76% Downside

Current Analyst Ratings Breakdown

Latest MXCT, SLP, NAUT, and LAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/12/2026
MaxCyte, Inc. stock logo
MXCT
MaxCyte
Set Price Target$4.00
11/4/2026
Standard BioTools Inc. stock logo
LAB
Standard BioTools
Reiterated RatingSell (D)
11/4/2026
MaxCyte, Inc. stock logo
MXCT
MaxCyte
DowngradeSell (D-) ➝ Sell (E+)
10/28/2026
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
UpgradeSell (E+) ➝ Sell (D)
10/22/2026
MaxCyte, Inc. stock logo
MXCT
MaxCyte
UpgradeSell (E+) ➝ Sell (D-)
10/7/2026
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
Dropped CoverageNeutral
10/6/2026
MaxCyte, Inc. stock logo
MXCT
MaxCyte
DowngradeSell (D-) ➝ Sell (E+)
10/6/2026
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
Reiterated RatingSell (D+)
9/30/2026
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
UpgradeHold
9/29/2026
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
Initiated CoverageBuy$3.50
9/29/2026
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
UpgradeStrong-Buy
(Data available from 11/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Standard BioTools Inc. stock logo
LAB
Standard BioTools
$85.33M2.64N/AN/A$1.41 per share0.40
MaxCyte, Inc. stock logo
MXCT
MaxCyte
$33.03M3.91N/AN/A$1.46 per share0.86
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
N/AN/AN/AN/A$0.92 per shareN/A
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
$82.06M4.56$1.43 per share12.93$6.20 per share2.98
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Standard BioTools Inc. stock logo
LAB
Standard BioTools
-$74.90M$0.22N/AN/AN/A157.62%-5.30%-4.46%N/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
-$44.63M-$0.26N/AN/AN/A-81.40%-15.05%-12.79%N/A
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
-$59M-$0.46N/AN/AN/AN/A-42.68%-34.39%N/A
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
-$64.72M$0.4046.25N/AN/A9.88%13.50%12.45%12/7/2026 (Estimated)

Latest MXCT, SLP, NAUT, and LAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
12/7/2026Q4 2026
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
$0.14N/AN/AN/A$19.18 millionN/A
11/10/2026Q3 2026
MaxCyte, Inc. stock logo
MXCT
MaxCyte
-$0.0775-$0.05+$0.0275-$0.05$7.39 million$8.16 million
11/3/2026Q3 2026
Standard BioTools Inc. stock logo
LAB
Standard BioTools
-$0.02$0.03+$0.05$0.03$18.80 million$19.39 million
10/27/2026Q3 2026
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
-$0.14-$0.12+$0.02-$0.12$0.21 million$0.23 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Standard BioTools Inc. stock logo
LAB
Standard BioTools
N/AN/AN/AN/AN/A
MaxCyte, Inc. stock logo
MXCT
MaxCyte
N/AN/AN/AN/AN/A
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
N/AN/AN/AN/AN/A
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
$0.241.30%-100.00%60.00%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Standard BioTools Inc. stock logo
LAB
Standard BioTools
N/A
9.75
9.40
MaxCyte, Inc. stock logo
MXCT
MaxCyte
N/A
7.83
7.37
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
N/A
9.25
9.25
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
N/A
5.54
5.54

Institutional Ownership

CompanyInstitutional Ownership
Standard BioTools Inc. stock logo
LAB
Standard BioTools
53.74%
MaxCyte, Inc. stock logo
MXCT
MaxCyte
68.81%
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
50.71%
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
78.08%

Insider Ownership

CompanyInsider Ownership
Standard BioTools Inc. stock logo
LAB
Standard BioTools
26.81%
MaxCyte, Inc. stock logo
MXCT
MaxCyte
4.10%
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
41.10%
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
19.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Standard BioTools Inc. stock logo
LAB
Standard BioTools
389394.79 million288.95 millionOptionable
MaxCyte, Inc. stock logo
MXCT
MaxCyte
91103.25 million99.02 millionOptionable
Nautilus Biotechnology, Inc. stock logo
NAUT
Nautilus Biotechnology
130127.37 million75.02 millionOptionable
Simulations Plus, Inc. stock logo
SLP
Simulations Plus
16020.23 million16.36 millionOptionable

Recent News About These Companies

Altaris Completes Acquisition of Simulations Plus

New MarketBeat Followers Over Time

Media Sentiment Over Time

Standard BioTools stock logo

Standard BioTools NASDAQ:LAB

$0.57 +0.03 (+5.67%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$0.57 0.00 (0.00%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

MaxCyte stock logo

MaxCyte NASDAQ:MXCT

$1.25 +0.08 (+6.84%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$1.36 +0.11 (+8.80%)
As of 05:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Nautilus Biotechnology stock logo

Nautilus Biotechnology NASDAQ:NAUT

$2.43 +0.07 (+2.97%)
Closing price 11/18/2026 04:00 PM Eastern
Extended Trading
$2.46 +0.03 (+1.23%)
As of 05:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Simulations Plus stock logo

Simulations Plus NASDAQ:SLP

$18.50 0.00 (0.00%)
As of 11/6/2026

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. The company also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, RENAsym, IPFsym, and MITOsym products. In addition, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, it offers creative and insightful consulting services to support its quantitative systems pharmacology/quantitative systems toxicology modelling. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.